Initial Approval: October 9, 2013

Revised Date: April 9, 2014

CRITERIA FOR PRIOR AUTHORIZATION

Mekinist® (trametinib)

PROVIDER GROUP Pharmacy

MANUAL GUIDELINES The following drug requires prior authorization:

Trametinib (Mekinist)

CRITERIA FOR MEKINIST SINGLE AGENT TREATMENT Must meet all of the following:

Patient must have a diagnosis of unresectable or metastatic melanoma

- Patient must have a mutation of BRAF V600E or V600K
- Patient must not have received previous treatment with a BRAF-inhibitor

LENGTH OF APPROVAL 12 months

CRITERIA FOR MEKINIST COMBINATION TREATMENT Must meet all of the following:

- Patient must have a diagnosis of unresectable or metastatic melanoma
- Patient must have a mutation of BRAF V600E or V600K
- Must be used in combination with dabrafenib

LENGTH OF APPROVAL 12 months